Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Opus Genetics (NASDAQ:IRD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.
Institutional and Insider Ownership
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by company insiders. Comparatively, 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Cardiff Oncology and Opus Genetics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiff Oncology | $590,000.00 | 123.80 | -$45.85 million | ($0.60) | -1.56 |
| Opus Genetics | $14.20 million | 23.92 | -$49.59 million | ($1.35) | -3.04 |
Cardiff Oncology has higher earnings, but lower revenue than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Cardiff Oncology has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Cardiff Oncology and Opus Genetics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiff Oncology | 1 | 3 | 3 | 0 | 2.29 |
| Opus Genetics | 1 | 1 | 16 | 1 | 2.89 |
Cardiff Oncology presently has a consensus target price of $7.50, suggesting a potential upside of 698.72%. Opus Genetics has a consensus target price of $12.71, suggesting a potential upside of 209.35%. Given Cardiff Oncology’s higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Opus Genetics.
Profitability
This table compares Cardiff Oncology and Opus Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
| Opus Genetics | -1,091.82% | N/A | -150.13% |
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
